4/A: ProMIS Neurosciences Amends Warrant Exercise Price

An amended SEC filing reveals a correction to the exercise price of warrants by a significant holder, impacting capital raised and ownership stake.

Summary

• Michael S. Gordon, through Title 19 Promis, filed an amended Form 4 to correct the exercise price of Tranche A, B, and C common share purchase warrants.
• The corrected exercise price for all three tranches is $0.83518 per warrant share, previously misstated as $0.83158.
• On July 25, 2025, Title 19 Promis exercised 119,800 warrants from each of Tranche A, B, and C, totaling 359,400 warrants.
• The original exercise prices for these warrants were $2.02 for Tranche A and B, and $2.50 for Tranche C, but were exercised at a significantly reduced price of $0.83518 following an offer and acceptance by the Issuer.
• Following these transactions, Michael S. Gordon, as the sole manager of Title 19 Promis, continues to indirectly beneficially own 345,316 Tranche A, 345,316 Tranche B, and 345,316 Tranche C common share purchase warrants, totaling 1,035,948 remaining warrants.
• The reporting person's indirect ownership percentage dropped below 10% as of the amendment filing date (August 14, 2025), based on 51,806,497 common shares outstanding as of August 13, 2025.

Sentiment

Score: 5

Explanation: The company received a cash infusion, and a significant holder maintains substantial warrant holdings, which are positive. However, the warrants were exercised at a considerable discount to their original prices, indicating less favorable terms for the company's capital raising.

Positives

• The company received approximately $300,200 in cash from the exercise of 359,400 warrants.
• The reporting person, Michael S. Gordon, continues to hold a substantial number of warrants (over 1 million total across tranches), indicating continued long-term interest in the company.

Negatives

• Warrants were exercised at a significantly reduced price of $0.83518 per share, compared to their original exercise prices of $2.02 (Tranche A & B) and $2.50 (Tranche C), resulting in less capital raised per share than initially planned.
• The reporting person's indirect ownership percentage dropped below 10% as of the amendment filing date.

Risks

• The exercise of warrants at a significantly reduced price could imply a lower perceived value of the company's shares or a need for immediate capital, potentially leading to future dilution if more warrants are exercised at similar discounts.
• Future warrant exercises, particularly those tied to clinical trial data announcements (PMN310 6-month and 12-month data), could lead to further dilution.

Future Outlook

The expiration of remaining Tranche A and B warrants is tied to the public announcement of 6-month and 12-month data, respectively, from cohorts treated with single ascending doses of PMN310, indicating upcoming milestones related to the company's clinical trials.

Management Comments

• Michael S. Gordon is the sole manager of Title 19 Promis, the entity that exercised the warrants.
• The reporting person's ownership dropped below 10% as of the date of filing this amended Form 4, based on the Issuer's Form 10-Q filed on August 13, 2025, which stated 51,806,497 Common Shares outstanding.

Industry Context

This filing is a standard insider transaction disclosure (Form 4/A) and does not provide broader industry context or trends. It primarily details a specific financial transaction and ownership change within ProMIS Neurosciences Inc., a biotechnology company focused on neurodegenerative diseases.

Comparison to Industry Standards

• NA

Related Party Transactions

• The transaction involves Michael S. Gordon, the sole manager of Title 19 Promis, exercising warrants in ProMIS Neurosciences Inc., where he holds an 'Other' relationship (likely a significant investor or affiliate).

Stakeholder Impact

• Shareholders: The exercise of warrants at a discounted price could be dilutive to existing shareholders if the market price was higher than the exercise price, but it also brings in capital.
• Company: Receives capital from the warrant exercise, supporting operations or development.

Next Steps

• Public announcement via press release or Current Report on Form 8-K of 6-month data from cohorts treated with single ascending doses of PMN310, which will trigger the expiration of remaining Tranche A warrants.
• Public announcement via press release or Current Report on Form 8-K of 12-month data from cohorts treated with single ascending doses of PMN310, which will trigger the expiration of remaining Tranche B warrants.

Key Dates

Recommendation

While the company received a cash infusion from the warrant exercise, the significant discount at which the warrants were exercised raises concerns about capital efficiency. The continued substantial warrant holdings by a key investor provide some stability. This filing primarily corrects a detail in an insider transaction and does not present a strong catalyst for a 'buy' or 'sell' recommendation without broader financial and clinical context.

Keywords

ProMIS Neurosciences, PMN, SEC Form 4/A, Warrant Exercise, Insider Trading, Beneficial Ownership, Equity Dilution, Biotechnology, Clinical Trials, PMN310